CIC
FHTX icon

Cornercap Investment Counsel’s Foghorn Therapeutics FHTX Stock Holding History

Cornercap Investment Counsel’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,147
Closed -$122K – 494
2024
Q3 		$122K Sell
13,147
-12,420
-49% -$89.9K 0.04% 488
2024
Q2 		$147K Sell
25,567
-252
-1% -$1.5K 0.02% 558
2024
Q1 		$173K Hold
25,819
– – 0.03% 577
2023
Q4 		$167K Hold
25,819
– – 0.03% 543
2023
Q3 		$129K Sell
25,819
-344
-1% -$2.65K 0.02% 526
2023
Q2 		$184K Hold
26,163
– – 0.03% 523
2023
Q1 		$162K Hold
26,163
– – 0.03% 522
2022
Q4 		$167K Buy
+26,163
New +$197K 0.03% 522

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cornercap Investment Counsel's FHTX Position: Q4 2024 in Review

Cornercap Investment Counsel sold out of Foghorn Therapeutics (FHTX) in Q4 2024, closing a stake of 13,147 shares — an estimated $122K sold.

Cornercap Investment Counsel first reported a position in FHTX in Q4 2022 and held it in 8 quarters. The position peaked at $184K in Q2 2023. 87 funds tracked by Wall St. Rank hold FHTX as of Q4 2024.

  • Cornercap Investment Counsel reported no remaining Foghorn Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 13,147 Foghorn Therapeutics shares in Q4 2024, an estimated $122K.
  • Cornercap Investment Counsel first reported a position in Foghorn Therapeutics in Q4 2022 and held it in 8 quarters.
  • Cornercap Investment Counsel's Foghorn Therapeutics position peaked at $184K in Q2 2023.
  • 87 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q4 2024.

Based on Cornercap Investment Counsel's 13F filing for Q4 2024, filed 12 Feb 2025.